The pathogenesis and clinical features of diabetic cardiomyopathy have been well-studied
in the past decade, but effective approaches to prevent and treat this disease are limited …

Heart failure (HF) is a growing public health issue. As many as 1 in 5 people are expected to
develop HF during their lifetime, 1 with an estimated 63 million people affected worldwide. 2 …

Abstract Treatment with sodium-glucose co-transporter-2 inhibitors induces an initial 3–5
ml/min/1.73 m 2 decline in estimated glomerular filtration rate (eGFR). Although considered …

The heart failure epidemic is growing and its prevention, in order to reduce associated
hospital readmission rates and its clinical and economic burden, is a key issue in modern …

Diabetes is the most frequent cause of chronic kidney disease (CKD), leading to nearly half
of all cases of kidney failure requiring replacement therapy. The principal cause of death …

Patients with type 2 diabetes (T2D) are often overweight/obese and affected by arterial
hypertension, dyslipidaemia, and have high serum levels of uric acid. Moreover, T2D patient …

Background: Sodium–glucose cotransporter-2 inhibitors (SGLT2is) decrease serum urate
levels, but whether this translates into prevention of recurrent flares among patients with …

Abstract Real-world evidence (RWE), the understanding of treatment effectiveness in clinical
practice generated from longitudinal patient-level data from the routine operation of the …

Importance Sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy has been associated
with cardiovascular benefits and a few adverse events; however, whether the comparative …

Heart failure (HF) continues to be a serious public health challenge despite significant
advancements in therapeutics and is often complicated by multiple other comorbidities. Of …